rilpivirine (TMC 278)

Rilpivirine as good as efavirenz

Graham Stocks — Wed, 23 Nov 2011 19:54:17 -0800

Dr Mark Bloch from Holdsworth House in Sydney presented the 48-week results of the combined ECHO and THRIVE studies which determined that the new NNRTI rilpivirine (RPV) is as effective as efavirenz (EFV) for first-line treatment.

Everyone in the studies received a nucleoside backbone to their treatment – in ECHO it was Truvada, in THRIVE it was tenfovir/3TC or abacavir/3TC.

News from IAS 2010

Graham Stocks — Wed, 01 Sep 2010 22:09:07 -0700

Adrian Ogier gives a round up of treatments news from the Vienna Conference.

Rilpivirine (TMC-278)

John Daye — Tue, 23 Sep 2008 20:42:50 -0700

Follow-up results from a Phase IIA smaller clinical trial designed to establish whether a drug is effective. Phase II studies are conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks. If there is evidence that the drug is effective, a Phase III study is undertaken, with a larger number of participaants, to confirm this. study of rilpivirine (TMC-278), Tibotec’s experimental(Of a drug) Not licensed for use in humans, or as a treatment for a particular condition. Experimental drugs are studied in clinical trials to determine their safety and efficacy, and are sometimes made available via Special Access Schemes prior to their approval. next generation NNRTI, indicate that when combined with Truvada or Combivir, rilpivirine has comparable results to the leading NNRTI, efavirenz.

AIDS 2008: Is the HIV drug pipeline drying up?

David Menadue — Tue, 23 Sep 2008 19:21:56 -0700

The International AIDS Conference heard promising reports about the newer HIV treatments designed to help treat people with advanced and drug-resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. HIV, all of which are now available in Australia.

Good news, bad news: report from CROI

admin — Tue, 25 Mar 2008 18:58:42 -0700

John Daye, NAPWA's Health, Treatments & Research Portfolio Co-Convenor reports from the 15th Conference on Retroviruses and Opportunistic Infections (CROI) held in Boston, USA from 3-6 February 2008

CROI 2007: A great leap forward

Paul Kidd — Wed, 21 Mar 2007 07:10:12 -0700

A major scientific conference on HIV has wound up with promising news on treatments which could signal a significant improvement in HIV treatment for the first time in some years.

The bleeding edge

John Daye — Wed, 18 May 2005 07:00:25 -0700

The annual Retrovirus Conference is a key event on the HIV scientific calendar, and regularly highlights the most exciting ‘bleeding edge’ developments from the world of HIV science.